Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions
Mehrdad Fathi(Kurdistan University of Medical Sciences), Farhad Jadidi-Niaragh(Tabriz University of Medical Sciences), Mozhdeh Sojoodi(Harvard University), Armin Ahmadi(University of Alabama in Huntsville), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Seyed‐Mostafa Razavi(Stanford University), Afshin Namdar(University of Toronto), Sharareh Gholamin(Institut de génétique et de développement de Rennes), Farbod Ebrahimi(North Carolina Agricultural and Technical State University)
Cited by 16
Related Papers
Unlimited in vitro expansion of adult bi‐potent pancreas progenitors through the Lgr5/R‐spondin axis
|The EMBO Journal|2013|721
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
BET Bromodomain Inhibition of <i>MYC</i> -Amplified Medulloblastoma
|Clinical Cancer Research|2013|354
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
|International Journal of Molecular Sciences|2014|202